India, July 28 -- Celcuity Inc. (CELC) has announced positive topline results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 clinical trial, and shares are up over 200% at $44.
The Phase 3 VIKTORIA-1 trial is evaluating the company's lead drug candidate, Gedatolisib, in combination with fulvestrant, with and without palbociclib, in HR+/HER2- advanced breast cancer patients who have received prior treatment with a CDK4/6 inhibitor. The study includes two cohorts - the PIK3CA wild-type cohort and the PIK3CA mutant cohort.
The results from the PIK3CA wild-type cohort of the VIKTORIA-1 trial, reported today, show that the combination of Gedatolisib, palbociclib, and fulvestrant, referred to as the Gedatolisib triplet, significantl...